Sitagliptin, an orally available dipeptidyl peptidase-4(DPP-IV) inhibitor developed to be used as a once daily treatment for diabetes mellitus type II (T2DM) .The present work was carried out to study the renoprotective effect of sitagliptin on experimentally induced type II diabetes mellitus in rats. To study the effect of sitagliptin on diabetic nephropathy,18 male albino rats were classified into 3 equal groups (6 rats in each group).First group which is control group. (T2DM) was induced in the other groups by a single intraperitonial (i.p) injection of (65 mg/kg body weight) streptozotocin (STZ), 15 minutes (min) after (i.p) administration of 110 mg/kg body weight of nicotinamide. 2nd group was not treated, 3rd group was treated with oral sitagliptin (10
mg/kg/day) for 6 weeks from induction of diabetes mellitus. The obtained results in the current work revealed that treatment with oral sitagliptin in male albino diabetic rats leads to normalization of diabetic nephropathy parameters as regard fasting blood glucose, serum urea& creatinine, 24-h urinary albumin exeretion (UAE), renal blood flow changes & histopathological examination of the kidney.
Conclusively: Sitagliptin prevents diabetic nephropathy development in diabetic rats. |
